MétaCan
Menu
← Back to cohort
Record W2016573373 · doi:10.1016/j.jalz.2011.05.2010

O4‐06‐07: Imaging and cerebrospinal fluid biomarker results of a phase II dose‐ranging study of ELND005 (Scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease

2011· article· en· W2016573373 on OpenAlexaff
Anton P. Porsteinsson, Reisa A. Sperling, Stephen Salloway, Ron Keren, Christopher van Dyck, Pierre N. Tariot, Douglas L. Arnold, Gerald Crans, R Hernandez, Earvin Liang, Menghis Bairu, Jesse M. Cedarbaum, Aleksandra Pastrak, Susan Abushakra

Bibliographic record

VenueAlzheimer s & Dementia · 2011
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsInterface Biologics (Canada)NeuroRx Research (Canada)University Health Network
Fundersnot available
KeywordsPlaceboBiomarkerMedicineCerebrospinal fluidClinical endpointInternal medicinePopulationGastroenterologyAmyloid betaUrologyNuclear medicinePathologyRandomized controlled trialDiseaseChemistry

Abstract

fetched live from OpenAlex

ELND005 (scyllo-inositol) is being investigated as a potential disease modifying oral agent for the treatment of Alzheimer's disease (AD). ELND005 inhibits aggregation of beta-amyloid (Abeta) and decreases plaque burden intransgenic TgCRND8 mice (McLaurin et al., 2006). In addition to clinical outcomes, this study investigated the effects of ELND005 on volumetric MRI measures (vMRI) and cerebrospinal fluid (CSF) biomarkers. Of 353 mild/moderate patients randomized to ELND005 (250, 1000, or 2000mg) or placebo twice daily for 78weeks, 351 received study drug. Brain ventricular volume (VV) was designated as the key imaging biomarker; exploratory endpoints included whole brain volume, average hippocampal volume, and cortical ribbon thickness. MRIs were performed in all patients at baseline and every 24 weeks. CSF samples from a subset of patients at baseline, 24 weeks, and 78 weeks were tested for Aß40, Aß42, tau, and p-tau181 levels. All primary anaylses were performed using a mixed-effects model repeated measures analysis. After elective discontinuation of the 2 high-dose groups due to safety findings, the primary analysis compared the 250mg and placebo groups. In the overall population, the VV increase at week 78 was greater for ELND005 than placebo (VV increase of 3.2cm;p = 0.049; n = 84/82 in 250mg/placebo), while other brain volume measures were not significant. In mild patients, who showed a positive trend on this study's primary cognitive endpoint (Salloway et al, submitted), the VV increase of 0.3cm was not significant. In mild/moderate patients, CSF biomarker changes were not significant at 24 weeks, but CSF Aß42 was significantly decreased at 78 weeks (p = 0.009, n = 19/14 in 250 mg/placebo), other CSF biomarker changes were not significant. Patients treated with ELND005 250mg demonstrated a significant decrease in CSF Aß42 levels and a small, but significant,increase in ventricular volume after 78 weeks of treatment. Similar MRI findings have been reported in clinical trials with other amyloid-targeted therapies. The time course of CSF Aß42 reduction may reflect a gradual decrease in brain amyloid pathology, consistent with the effects of scyllo-inositol in transgenic mice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.337
Teacher spread0.282 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→